Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499900 · ClinicalTrials.gov registry record · Phase 4
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
A Phase 4 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 861
- Enrollment target
NCT02499900 is a Phase 4 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 861 participants.
The verdict
NCT02499900, a Phase 4 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 861 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.
Interventions
- DRUG Copaxone®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 861 participants |
| Start Date | 2015-08-10 |
| Est. Completion | 2017-06-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02499900
The ClinicalTrials.gov registry entry for NCT02499900 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 861 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Copaxone® is the first listed.
NCT02499900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02499900 about?
NCT02499900 is a clinical study titled "Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®". The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.
What is the current status of trial NCT02499900?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 861 participants. The study started on 2015-08-10. Estimated completion is 2017-06-02.
What interventions are being tested in trial NCT02499900?
The interventions under investigation include: Copaxone® (DRUG).
Who is sponsoring clinical trial NCT02499900?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.